Regulation of p53 stability and apoptosis by a ROR agonist

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Wang, Yongjun ^a   Solt, Laura A ^a   Kojetin, Douglas J ^a   Burris, Thomas P ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN P53; RETINOIC ACID RECEPTOR RELATED ORPHAN RECEPTOR ALPHA AGONIST; RETINOID RELATED ORPHAN RECEPTOR ALPHA; SR 1078; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; RORA PROTEIN, HUMAN; SOX4 PROTEIN, HUMAN; TRANSCRIPTION FACTOR SOX;

APOPTOSIS; ARTICLE; CANCER CELL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; NONHUMAN; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; REGULATORY MECHANISM; CELL CYCLE; CELL STRAIN HEPG2; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; CELL CYCLE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; NUCLEAR RECEPTOR SUBFAMILY 1, GROUP F, MEMBER 1; SOXC TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84859626370     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034921     Document Type: Article

References (33)

1. Vogelstein B, Lane D, Levine AJ, (2000) Surfing the p53 network. Nature 408: 307-310.
2. Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, et al. (2001) Rotating night shifts and risk of breast cancer in women participating in the nurses' health study. Journal of the National Cancer Institute 93: 1563-1568.
3. Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, et al. (2003) Night-shift work and risk of colorectal cancer in the Nurses' Health Study. Journal of the National Cancer Institute 95: 825-828.
4. Megdal SP, Kroenke CH, Laden F, Pukkala E, Schernhammer ES, (2005) Night work and breast cancer risk: A systematic review and meta-analysis. European Journal of Cancer 41: 2023-2032.
5. Hansen J, (2001) Increased breast cancer risk among women who work predominantly at night. Epidemiology 12: 74-77.
6. Straif K, Baan R, Grosse Y, Secretan B, El Ghissassi F, et al. (2007) Carcinogenicity of shift-work, painting, and fire-fighting. Lancet Oncology 8: 1065-1066.
7. Filipski E, Delaunay F, King VM, Wu MW, Claustrat B, et al. (2004) Effects of chronic jet lag on tumor progression in mice. Cancer Research 64: 7879-7885.
8. Shah PN, Mhatre MC, Kothari LS, (1984) EFFECT OF MELATONIN ON MAMMARY CARCINOGENESIS IN INTACT AND PINEALECTOMIZED RATS IN VARYING PHOTOPERIODS. Cancer Research 44: 3403-3407.
9. Filipski E, King VM, Li XM, Granda TG, Mormont MC, et al. (2002) Host circadian clock as a control point in tumor progression. Journal of the National Cancer Institute 94: 690-697.
10. van den Heiligenberg S, Depres-Brummer P, Barbason H, Claustrat B, Reynes M, et al. (1999) The tumor promoting effect of constant light exposure on diethylnitrosamine-induced hepatocarcinogenesis in rats. Life Sciences 64: 2523-2534.
11. Lin YM, Chang JH, Yeh KT, Yang MY, Li TC, et al. (2008) Disturbance of Circadian Gene Expression in Hepatocellular Carcinoma. Molecular Carcinogenesis 47: 925-933.
12. Kuo SJ, Chen ST, Yeh KT, Hou MF, Chang YS, et al. (2009) Disturbance of circadian gene expression in breast cancer. Virchows Archiv 454: 467-474.
13. Chen ST, Choo KB, Hou MF, Yeh KT, Kuo SJ, et al. (2005) Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. Carcinogenesis 26: 1241-1246.
14. Yang XM, Wood PA, Oh EY, Du-Quiton J, Ansell CM, et al. (2009) Down regulation of circadian clock gene Period 2 accelerates breast cancer growth by altering its daily growth rhythm. Breast Cancer Research and Treatment 117: 423-431.
15. Sato TK, Panda S, Miraglia LJ, Reyes TM, Rudic RD, et al. (2004) A functional genomics strategy reveals rora as a component of the mammalian circadian clock. Neuron 43: 527-537.
16. Akashi M, Takumi T, (2005) The orphan nuclear receptor ROR alpha regulates circadian transcription of the mammalian core-clock Bmal1. Nature Structural & Molecular Biology 12: 441-448.
17. Guillaumond F, Dardente H, Giguere V, Cermakian N, (2005) Differential control of Bmal1 circadian transcription by REV-ERB and ROR nuclear receptors. Journal of Biological Rhythms 20: 391-403.
18. Crumbley C, Burris TP, (2011) Direct Regulation of CLOCK Expression by REV-ERB. PloS One 6.
19. Crumbley C, Wang Y, Kojetin DJ, Burris TP, (2010) Characterization of the core mammalian clock component, NPAS2, as a REV-ERBalpha/RORalpha target gene. Journal of Biological Chemistry 285: 35386-35392.
20. Chauvet C, Bois-Joyeux B, Danan JL, (2002) Retinoic acid receptor-related orphan receptor (ROR) alpha 4 is the predominant isoform of the nuclear receptor ROR alpha in the liver and is up-regulated by hypoxia in HepG2 human hepatoma cells. Biochemical Journal 364: 449-456.
21. Zhu Y, McAvoy S, Kuhn R, Smith DI, (2006) RORA, a large common fragile site gene, is involved in cellular stress response. Oncogene 25: 2901-2908.
22. Pan X, Zhao J, Zhang WN, Li HY, Mu R, et al. (2009) Induction of SOX4 by DNA damage is critical for p53 stabilization and function. Proceedings of the National Academy of Sciences of the United States of America 106: 3788-3793.
23. Wang Y, Kumar N, Solt LA, Richardson TI, Helvering LM, et al. (2010) Modulation of RORalpha and RORgamma activity by 7-oxygenated sterol ligands. Journal of Biological Chemistry 285: 5013-5025.
24. Wang Y, Kumar N, Nuhant P, Cameron MD, Istrate MA, et al. (2010) Identification of SR1078, a Synthetic Agonist for the Orphan Nuclear Receptors RORA and RORG. ACS Chemical Biology pp. 1029-1034.
25. Solt LA, Kumar N, Nuhant P, Wang YJ, Lauer JL, et al. (2011) Suppression of T(H)17 differentiation and autoimmunity by a synthetic ROR ligand. Nature 472: 491-494.
26. Kumar N, Kojetin DJ, Solt LA, Kumar KG, Nuhant P, et al. (2011) Identification of SR3335 (ML-176): A Synthetic ROR alpha Selective Inverse Agonist. ACS Chemical Biology 6: 218-222.
27. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B, (1992) AMPLIFICATION OF A GENE ENCODING A P53-ASSOCIATED PROTEIN IN HUMAN SARCOMAS. Nature 358: 80-83.
28. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP, (2009) Awakening guardian angels: drugging the p53 pathway. Nature Reviews Cancer 9: 862-873.
29. Kim H, Lee JL, Lee G, Bhin J, Oh SK, et al. (2011) DNA damage-induced RORalpha is crucial for p53 stabilization and increased apoptosis. Molecular Cell 44: 797-810.
30. Wang YJ, Solt LA, Burris TP, (2010) Regulation of FGF21 Expression and Secretion by Retinoic Acid Receptor-related Orphan Receptor alpha. Journal of Biological Chemistry 285: 15668-15673.
31. Wang YJ, Rogers PM, Stayrook KR, Su C, Varga G, et al. (2008) The Selective Alzheimer's Disease Indicator-1 Gene (Seladin-1/DHCR24) Is a Liver X Receptor Target Gene. Molecular Pharmacology 74: 1716-1721.
32. Wang Y, Rogers PM, Su C, Varga G, Stayrook KR, et al. (2008) Regulation of cholesterologenesis by the oxysterol receptor, LXRalpha. J Biol Chem 283: 26332-26339.
33. Stayrook KR, Rogers PM, Savkur RS, Wang Y, Su C, et al. (2008) Regulation of human 3alpha-hydroxysteroid dehydrogenase (AKR1C4) expression by the liver X receptor alpha. Mol Pharmacol 73: 607-612.